New drug ORB-011 tested in advanced cancer patients
Disease control
Ongoing
This early-stage study tests a new drug, ORB-011, in 55 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check if the drug is safe and to find the best dose for future studies. Participants will be monitored for side effects and h…
Phase: PHASE1 • Sponsor: Orionis Biosciences Inc • Aim: Disease control
Last updated May 17, 2026 15:14 UTC